Proactive Investors - Run By Investors For Investors

Proteomics International to present at diabetes conference featuring PromarkerD test

In parallel with the global roll-out of PromarkerD to markets, the company is pursuing registration of the kit version of the test for larger-scale adoption.
Laboratory work
PromarkerD is a predictive diagnostic test for diabetic kidney disease

Proteomics International Laboratories Ltd (ASX:PIQ) has been invited to feature on the American Diabetes Association (ADA) TV News Network as a key opinion leader on diabetic kidney disease diagnostics during the ADA 79th Scientific Sessions conference in San Francisco.

The company has been asked to feature the Promarker D, a blood test which can diagnose and predict whether a patient will develop diabetic kidney disease and can predict the onset of diabetic kidney disease before clinical symptoms appear.

Proteomics’ attendance at the BIO International Convention in Philadelphia and now the ADA conference showcases PromarkerD and provides the opportunity to meet with tier-1 national diagnostic groups.

“A major difference for patients”

Proteomics managing director Richard Lipscombe said: “The PromarketD test can make a major difference for patients, healthcare providers and insurance companies because it could cut dramatically the number of people who are unaware, they have progressive kidney disease.

“An early diagnosis will enable patients to do something about it immediately and so reduce the potential of costly kidney dialysis.”

PromarketD has been rated the world’s leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its independent industry report titled Biomarkers Enabling Diabetes and Obesity Management.

The test has also received patent protection in several major jurisdictions including the USA, China, Europe and Japan with others pending.

View full PIQ profile View Profile

Proteomics International Laboratories Ltd Timeline

Related Articles

A paper rocket is ready to launch on a surgeon's scissors
March 29 2019
The company hopes to improve its share price with ADAPT technology successes.
Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
seeds in a bowl
March 08 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use